Arkolith/Insider Trading/ESPR/Form 4

Halladay Benjamin

Chief Financial OfficerEsperion Therapeutics, Inc. (ESPR) · full profile →Form 4 · filed Jul 13, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
1 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 13, 2026Disposed to issuer(D)705K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 13, 2026Disposed to issuer(D)200K——0
Jul 13, 2026Disposed to issuer(D)213K——0
Jul 13, 2026Disposed to issuer(D)221K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-048000) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML